



Cite this: *Med. Chem. Commun.*,
2016, 7, 202

Correction: Syntheses and biological evaluations of highly functionalized hydroxamate containing and *N*-methylthio monobactams as anti-tuberculosis and β -lactamase inhibitory agents

Mark W. Majewski,^a Kyle D. Watson,^a Sanghyun Cho,^b Patricia A. Miller,^a
Scott G. Franzblau^b and Marvin J. Miller^{*a}

DOI: 10.1039/c5md90052b

www.rsc.org/medchemcomm

Correction for 'Syntheses and biological evaluations of highly functionalized hydroxamate containing and *N*-methylthio monobactams as anti-tuberculosis and β -lactamase inhibitory agents.

The authors regret that compound number 1 was used for two different compounds in the manuscript. In Fig. 2 compound numbers 1, 2 and 3 should be corrected to show a, b and c. The corrected figure is shown below.




Fig. 2

And consequently, the text on page 2, referring to Fig. 2, should be corrected to read: Reports of β -lactam compounds with potent anti-TB activity, however, have been scarce. Certain classic β -lactams can exhibit anti-TB activity when administered in combination with clavulanate, a β -lactamase inhibitor (Fig. 2, a).^{9,10} Furthermore, monobactam alkylthiols and halogen substituted aromatic monobactams have also demonstrated intrinsic activity (Fig. 2, b–c).^{11,12} In general, β -lactams have not been widely used in TB therapy for three major reasons: issues with permeability of the cell wall of *M. tb*, the persistent threat of inactivation by β -lactamases, and poor activity *in vivo*.¹³

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

^a Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA. E-mail: mmiller1@nd.edu; Fax: +1 574 631 6652; Tel: +1 574 631 7571

^b Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, MIC 964, Rm. 412, IL 60612, USA